Allora has postponed the initial unlocking of about 242.75 million ALLO tokens for its core contributors and supporters from November 11, 2026, to May 11, 2027. This delay affects a total pool of 485.5 million ALLO tokens, representing 48.55% of the total supply. On the new date, half of this pool will become available, with the remaining half vesting gradually over 18 months until November 2028. Other token distributions like staking and rewards remain on their original schedules, and token holders do not need to take any action. This change adjusts the timing but not the amount of token allocation in Allora's decentralized AI network.
Allora's token unlock delay is the subject, with market data as of Nov 12, 2026 05:22 WIB. For readers following cryptocurrency markets, here is Pluang's snapshot: out of 50 major cryptocurrencies, 27 rose and 22 fell today. Notable movers include FIL at Rp13.938 (+2.97%), XLM at Rp2.699 (+2.90%), and AVAX at Rp155.245 (+2.89%).
Ashland Inc.'s board of directors declared a quarterly cash dividend of $0.42 per share, payable on December 15, 2026, to shareholders of record as of December 1, 2026. This dividend reflects the company's ongoing commitment to returning value to sha...
AeroVironment secured a $405 million international order for its LOCUST X3 high-energy laser weapon systems, enhancing counter-drone defense capabilities in the Middle East amid rising regional security threats. Following the announcement, AeroVironm...
Vestas Wind Systems reported Q3 2026 earnings per share of $0.13 and revenue of $6.34 billion, both below analyst expectations. The company's profit was impacted by weak sales volume and a broken turbine blade. Following the earnings miss, Vestas' sh...
The global beverage market is projected to grow from $2.03 trillion in 2026 to $2.78 trillion by 2032, at a CAGR of 5.35%. Growth is fueled by rising demand for nonalcoholic and functional beverages, convenience packaging, and premium products for sp...
DelveInsight's 2026 report reveals more than 200 GLP-1 receptor agonists and incretin-based therapies are in development by over 180 companies, targeting conditions like type 2 diabetes, obesity, and related metabolic disorders. Key players such as E...
